Ming Su

Prof. Dr. Ming Su

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in TrAC Trends in Analytical Chemistry
Verified
Journal Article
Closed access
MSMing Su
Ming Su
PCPeiyun Chen
Peiyun Chen
HSHanwen Sun
Hanwen Sun

2 January 2023 in Chemosphere
Verified
Journal Article
Closed access
ZZZhe Zhao
Zhe Zhao
SLShumin Lin
Shumin Lin
ZYZhendong Yu
Zhendong Yu
MSMing Su
Ming Su
BLBolong Liang
Bolong Liang
XJXue-Hai Ju
Xue-Hai Ju

Verified
Journal Article
Open access
PDF file
YZYihua Zhang
Yihua Zhang
HLHui Li
Hui Li
XLXueli Liu
Xueli Liu
QWQiang Wang
Qiang Wang
DZDong Zhao
Dong Zhao
SSShigang Shen
Shigang Shen
This study aimed to explore the liver protective effects of a fourth-generation glycyrrhizic acid product (magnesium isoglycyrrhizinate injection, MII) in the treatment of mice with drug-induced liver injury—specifically, to determine its effects on plasma metabolites. Moreover, the possible mechanism of its intervention in lipid metabolism and amino acid metabolism through the liver protective effect was preliminarily explored, combined with network pharmacology. The liver injury model of mice was established using acetaminophen (APAP). The protective effect of MII on the mice model was evaluated using pathological tissue sections and biochemical indices such as alanine transaminase (ALT), aspartate aminotransferase (AST), and superoxide dismutase (SOD). Metabolomics analysis of plasma was performed using the UHPLC-QTOF/MS technique to screen for potential biomarkers and enriched metabolic pathways. The potential targets and pathways of MII were predicted by network pharmacology, and the mechanism was verified by Western blot analysis. MII significantly improved the pathological liver changes in mice with liver injury. The content of ALT and AST was decreased, and the activity of SOD was increased significantly (p < 0.05, 0.01). A total of 29 potential biomarkers were identified in the metabolomics analysis, mainly involving seven pathways, such as lipid metabolism and amino acid metabolism. A total of 44 intersection targets of MII in the treatment of liver injury were obtained by network pharmacology, involving lipid metabolism and other related pathways. Western blot analysis results showed that MII could significantly reduce the expression of JAK2 and STAT3. MII can effectively ameliorate liver injury in modeled mice through related pathways such as lipid metabolism and amino acid metabolism. This study could provide not only a scientific basis for the elucidation of the mechanism of action of MII in exerting a hepatoprotective effect, but also a reference for its rational clinical application.

20 September 2025 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
WCWeina Chai
Weina Chai
ZCZiyue Cao
Ziyue Cao
HTHaoyuan Tan
Haoyuan Tan
XHXiao He
Xiao He
JDJiangxue Dong
Jiangxue Dong
MSMing Su
Ming Su

29 March 2026 in Microchimica Acta
Verified
Journal Article
Closed access
HTHaoyuan Tan
Haoyuan Tan
XCXuefeng Cao
Xuefeng Cao
CXChenchen Xu
Chenchen Xu
YZYufan Zhang
Yufan Zhang
HLHaiyin Li
Haiyin Li
MSMing Su
Ming Su

20 August 2026 in Analytical Chemistry
Verified
Journal Article
Closed access
HLHaiyin Li
Haiyin Li
WWWendong Wang
Wendong Wang
HJHongqi Jiang
Hongqi Jiang
RHRuiqi Han
Ruiqi Han
JHJiayu He
Jiayu He
JCJianling Chen
Jianling Chen